Evidence map›Paper›PMID 28448457›Full record

Trial reportNutrients2017

Effects of Vitamin D Supplementation on Bone Turnover Markers: A Randomized Controlled Trial.

Verena Schwetz, Christian Trummer, Marlene Pandis, Martin R Grübler, Nicolas Verheyen, Martin Gaksch, Armin Zittermann, Winfried März, Felix Aberer, Angelika Lang and 6 more

Open access · goldAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Nutrients, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed, 1 pooled it
4.8field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 1 synthesis or guideline pooled it, 56 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Effect of isolated vitamin D supplementation on bone turnover markers in younger postmenopausal women: a randomized, double-blind, placebo-controlled trial.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2018
    Trial
  8. Effect of vitamin D3 on bone turnover markers in critical illness: post hoc analysis from the VITdAL-ICU study.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2017
    Trial
  9. Trial
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Review
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 3 institutions in 3 countries.

Verena SchwetzDepartment of Internal Medicine, Division of Endocrinology and Diabetology, Medical University of Graz, Graz 8036, Austria. verena.schwetz@medunigraz.at.
Christian TrummerDepartment of Internal Medicine, Division of Endocrinology and Diabetology, Medical University of Graz, Graz 8036, Austria. christian.trummer@medunigraz.at.
Marlene PandisDepartment of Internal Medicine, Division of Endocrinology and Diabetology, Medical University of Graz, Graz 8036, Austria. marlene.pandis@medunigraz.at.
Martin R GrüblerDepartment of Internal Medicine, Division of Endocrinology and Diabetology, Medical University of Graz, Graz 8036, Austria. martin.gruebler@gmx.net.
Nicolas VerheyenDepartment of Internal Medicine, Division of Cardiology, Medical University of Graz, Graz 8036, Austria. nicolas.verheyen@medunigraz.at.
Martin GakschDepartment of Internal Medicine, Division of Endocrinology and Diabetology, Medical University of Graz, Graz 8036, Austria. martin.gaksch@gmail.com.
Armin ZittermannClinic for Thoracic and Cardiovascular Surgery, Heart and Diabetes Center NRW, Bad Oeynhausen 32545, Germany. azittermann@hdz-nrw.de.
Winfried MärzClinical Institute of Medical and Chemical Laboratory Diagnostics, Medical University of Graz, Graz 8036, Austria. Winfried.Maerz@synlab.com.
Felix AbererDepartment of Internal Medicine, Division of Endocrinology and Diabetology, Medical University of Graz, Graz 8036, Austria. felix.aberer@medunigraz.at.
Angelika LangDepartment of Internal Medicine, Division of Endocrinology and Diabetology, Medical University of Graz, Graz 8036, Austria. angelika.lang@stud.medunigraz.at.
Gerlies TreiberDepartment of Internal Medicine, Division of Endocrinology and Diabetology, Medical University of Graz, Graz 8036, Austria. gerlies.treiber@medunigraz.at.
Claudia FriedlDepartment of Internal Medicine, Division of Nephrology, Medical University of Graz, Graz 8036, Austria. Claudia.Friedl2@klinikum-graz.at.
Barbara Obermayer-PietschDepartment of Internal Medicine, Division of Endocrinology and Diabetology, Medical University of Graz, Graz 8036, Austria. barbara.obermayer@medunigraz.at.
Thomas R PieberDepartment of Internal Medicine, Division of Endocrinology and Diabetology, Medical University of Graz, Graz 8036, Austria. thomas.pieber@medunigraz.at.
Andreas TomaschitzDepartment of Internal Medicine, Division of Cardiology, Medical University of Graz, Graz 8036, Austria. andreas.tomaschitz@gmx.at.
Stefan PilzDepartment of Internal Medicine, Division of Endocrinology and Diabetology, Medical University of Graz, Graz 8036, Austria. stefan.pilz@medunigraz.at.
Medical University of Graz · ATHeart and Diabetes Center North Rhine-Westphalia · DEUniversity of Bern · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Bone turnover markers (BTMs) are used to evaluate bone health together with bone mineral density and fracture assessment. Vitamin D supplementation is widely used to prevent and treat musculoskeletal diseases but existing data on vitamin D effects on markers of bone resorption and formation are inconsistent. We therefore examined the effects of vitamin D supplementation on bone-specific alkaline phosphatase (bALP), osteocalcin (OC), C-terminal telopeptide (CTX), and procollagen type 1 N-terminal propeptide (P1NP). This is a post-hoc analysis of the Styrian Vitamin D Hypertension Trial, a single-center, double-blind, randomized, placebo-controlled trial (RCT) performed at the Medical University of Graz, Austria (2011-2014). Two hundred individuals with arterial hypertension and 25-hydroxyvitamin D (25[OH]D) levels <75 nmol/L were randomized to 2800 IU of vitamin D daily or placebo for eight weeks. One hundred ninety-seven participants (60.2 ± 11.1 years; 47% women) were included in this analysis. Vitamin D had no significant effect on bALP (mean treatment effect (MTE) 0.013, 95% CI -0.029 to 0.056 µg/L;

Indexed as

AgedAlkaline PhosphataseBiomarkersBone RemodelingDouble-Blind MethodFemaleGene Expression RegulationHumansMaleMiddle AgedOsteocalcinPeptide FragmentsProcollagenVitamin D25-hydroxyvitamin DAlkaline PhosphataseBiomarkersOsteocalcinPeptide FragmentsProcollagenprocollagen Type I N-terminal peptideVitamin Dbone-specific alkaline phosphatasebone turnover markerscrosslapsosteocalcinprocollagen type 1 N-terminal propeptidevitamin D supplementation

Identifiers

PMID28448457
PMCPMC5452162
OpenAlexW2609966193

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.